OMO-1 reduces progression and enhances cisplatin efficacy in a 4T1-based non-c-MET addicted intraductal mouse model for triple-negative breast cancer

OMO-1 reduces progression and enhances cisplatin efficacy in a 4T1-based non-c-MET addicted intraductal mouse model for triple-negative breast cancer

Abstract c-MET is considered a driver of cancer progression, impacting tumor growth and tumor-supporting stroma. Here, we investigated the therapeutic efficacy of OMO-1, a potent and selective c-MET inhibitor, in an immunocompetent intraductal mouse model for triple-negative breast cancer (TNBC). OM...

Full description

Bibliographic Details
Main Authors: Jonas Steenbrugge, Niels Vander Elst, Kristel Demeyere, Olivier De Wever, Niek N. Sanders, Wim Van Den Broeck, Eric Ciamporcero, Timothy Perera, Evelyne Meyer
Format: Article
Language:English
Published: Nature Publishing Group 2021-03-01
Series:npj Breast Cancer
Online Access:https://doi.org/10.1038/s41523-021-00234-8

Internet

https://doi.org/10.1038/s41523-021-00234-8

Similar Items